New immune vaccine plus nivolumab for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies whether an individualized “neoantigen” cancer vaccine given to immune cells (dendritic cells) plus nivolumab can improve outcomes in people with liver cancer and/or colorectal cancer that has spread only to the liver. It focuses on tumors that can be removed with curative surgery (with or without local ablation) and on people with good enough liver and overall health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have either newly diagnosed or returning liver cancer (HCC) or colorectal cancer that has spread only to the liver (CRLM).
- Your scans must show no spread beyond the liver within 12 weeks before starting the study.
- Your liver tumor(s)/liver metastases must be treatable with curative surgery (sometimes plus local ablation).
- Your liver function must be fairly preserved (Child-Pugh score 5 or 6, plus blood tests showing safe liver, kidney, and blood counts).
- You should have a good performance status (ECOG 0 or 1) and meet required blood count and clotting thresholds within 28 days before enrollment.
- You cannot have had prior anti–PD-1/PD-L1 immune therapy or prior systemic HCC treatments like TACE/TACE-like procedures, SIRT, or SBRT for HCC.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether CVM-1118 given with nivolumab can help people with advanced, unresectable hepatocellular carcinoma (a type of liver cancer) that can’t be cured with surgery. It’s for patients whose cancer has worsened after earlier cancer medicines or treatments.
This Phase 2 trial studies whether adding a cancer vaccine (to help the immune system recognize your tumor) to two medicines—atezolizumab and bevacizumab—can better control unresectable or advanced liver cancer. It’s for people who haven’t had prior whole-body (systemic) cancer treatment.
This trial tests a combination of liver-directed chemotherapy (HEPZATO KIT) with a new immunotherapy called Opdualag for people whose melanoma has spread to the liver and who have not had many prior treatments.
This study tests a new way of giving immunotherapy drugs for advanced liver cancer that cannot be removed by surgery. The goal is to find the best dose for each patient, which may help control the cancer with fewer side effects.
This trial tests a combination of two immunotherapy drugs, nivolumab and ipilimumab, as a first treatment for liver cancer that cannot be removed by surgery or has come back after local treatments.
This trial tests a combination of a personalized immune cell treatment (made from your own cells) and a pneumococcal vaccine along with an “immune checkpoint” drug after high-dose radiation for certain unresectable liver cancers. The goal is to help your immune system better attack the cancer and to see how safe and effective this approach is.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.